430 related articles for article (PubMed ID: 24120854)
1. RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Ohga N; Hida K; Harashima H
J Control Release; 2014 Jan; 173():110-8. PubMed ID: 24120854
[TBL] [Abstract][Full Text] [Related]
2. Failure of active targeting by a cholesterol-anchored ligand and improvement by altering the lipid composition to prevent ligand desorption.
Yamamoto S; Sakurai Y; Harashima H
Int J Pharm; 2018 Jan; 536(1):42-49. PubMed ID: 29126905
[TBL] [Abstract][Full Text] [Related]
3. Targeted delivery of small interfering RNA to angiogenic endothelial cells with liposome-polycation-DNA particles.
Vader P; Crielaard BJ; van Dommelen SM; van der Meel R; Storm G; Schiffelers RM
J Control Release; 2012 Jun; 160(2):211-6. PubMed ID: 21983283
[TBL] [Abstract][Full Text] [Related]
4. Novel antiangiogenic therapy targeting biglycan using tumor endothelial cell-specific liposomal siRNA delivery system.
Maishi N; Sakurai Y; Hatakeyama H; Umeyama Y; Nakamura T; Endo R; Alam MT; Li C; Annan DA; Kikuchi H; Morimoto H; Morimoto M; Akiyama K; Ohga N; Hida Y; Harashima H; Hida K
Cancer Sci; 2022 May; 113(5):1855-1867. PubMed ID: 35266253
[TBL] [Abstract][Full Text] [Related]
5. Improvement of doxorubicin efficacy using liposomal anti-polo-like kinase 1 siRNA in human renal cell carcinomas.
Sakurai Y; Hatakeyama H; Akita H; Harashima H
Mol Pharm; 2014 Aug; 11(8):2713-9. PubMed ID: 24800640
[TBL] [Abstract][Full Text] [Related]
6. A pH-sensitive cationic lipid facilitates the delivery of liposomal siRNA and gene silencing activity in vitro and in vivo.
Sato Y; Hatakeyama H; Sakurai Y; Hyodo M; Akita H; Harashima H
J Control Release; 2012 Nov; 163(3):267-76. PubMed ID: 23000694
[TBL] [Abstract][Full Text] [Related]
7. Preparation of a Cyclic RGD: Modified Liposomal SiRNA Formulation for Use in Active Targeting to Tumor and Tumor Endothelial Cells.
Sakurai Y; Hada T; Harashima H
Methods Mol Biol; 2016; 1364():63-9. PubMed ID: 26472442
[TBL] [Abstract][Full Text] [Related]
8. Gene silencing via RNAi and siRNA quantification in tumor tissue using MEND, a liposomal siRNA delivery system.
Sakurai Y; Hatakeyama H; Sato Y; Hyodo M; Akita H; Harashima H
Mol Ther; 2013 Jun; 21(6):1195-203. PubMed ID: 23568259
[TBL] [Abstract][Full Text] [Related]
9. [Development of siRNA Delivery Targeting the Tumor Microenvironment with a New Functional Device].
Sakurai Y
Yakugaku Zasshi; 2019; 139(11):1357-1363. PubMed ID: 31685731
[TBL] [Abstract][Full Text] [Related]
10. Inhibiting tumor growth by targeting liposomally encapsulated CDC20siRNA to tumor vasculature: therapeutic RNA interference.
Majumder P; Bhunia S; Bhattacharyya J; Chaudhuri A
J Control Release; 2014 Apr; 180():100-8. PubMed ID: 24556418
[TBL] [Abstract][Full Text] [Related]
11. Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA.
Liu X; Wang W; Samarsky D; Liu L; Xu Q; Zhang W; Zhu G; Wu P; Zuo X; Deng H; Zhang J; Wu Z; Chen X; Zhao L; Qiu Z; Zhang Z; Zeng Q; Yang W; Zhang B; Ji A
Nucleic Acids Res; 2014 Oct; 42(18):11805-17. PubMed ID: 25223783
[TBL] [Abstract][Full Text] [Related]
12. Optimization of a siRNA Carrier Modified with a pH-Sensitive Cationic Lipid and a Cyclic RGD Peptide for Efficiently Targeting Tumor Endothelial Cells.
Hada T; Sakurai Y; Harashima H
Pharmaceutics; 2015 Sep; 7(3):320-33. PubMed ID: 26389942
[TBL] [Abstract][Full Text] [Related]
13. Self-crosslinked human serum albumin nanocarriers for systemic delivery of polymerized siRNA to tumors.
Son S; Song S; Lee SJ; Min S; Kim SA; Yhee JY; Huh MS; Chan Kwon I; Jeong SY; Byun Y; Kim SH; Kim K
Biomaterials; 2013 Dec; 34(37):9475-85. PubMed ID: 24050874
[TBL] [Abstract][Full Text] [Related]
14. Endosomal escape and the knockdown efficiency of liposomal-siRNA by the fusogenic peptide shGALA.
Sakurai Y; Hatakeyama H; Sato Y; Akita H; Takayama K; Kobayashi S; Futaki S; Harashima H
Biomaterials; 2011 Aug; 32(24):5733-42. PubMed ID: 21605898
[TBL] [Abstract][Full Text] [Related]
15. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
Amin M; Badiee A; Jaafari MR
Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
[TBL] [Abstract][Full Text] [Related]
16. The relationship between the cyclic-RGDfK ligand and αvβ3 integrin receptor.
Mondal G; Barui S; Chaudhuri A
Biomaterials; 2013 Aug; 34(26):6249-60. PubMed ID: 23702147
[TBL] [Abstract][Full Text] [Related]
17. Anti-angiogenic therapy via cationic liposome-mediated systemic siRNA delivery.
Tagami T; Suzuki T; Matsunaga M; Nakamura K; Moriyoshi N; Ishida T; Kiwada H
Int J Pharm; 2012 Jan; 422(1-2):280-9. PubMed ID: 22101286
[TBL] [Abstract][Full Text] [Related]
18. Efficient Packaging of Plasmid DNA Using a pH Sensitive Cationic Lipid for Delivery to Hepatocytes.
Sakurai Y; Matsuda T; Hada T; Harashima H
Biol Pharm Bull; 2015; 38(8):1185-91. PubMed ID: 26235581
[TBL] [Abstract][Full Text] [Related]
19. Efficient siRNA Delivery by Lipid Nanoparticles Modified with a Nonstandard Macrocyclic Peptide for EpCAM-Targeting.
Sakurai Y; Mizumura W; Murata M; Hada T; Yamamoto S; Ito K; Iwasaki K; Katoh T; Goto Y; Takagi A; Kohara M; Suga H; Harashima H
Mol Pharm; 2017 Oct; 14(10):3290-3298. PubMed ID: 28789523
[TBL] [Abstract][Full Text] [Related]
20. [Development of an efficient short interference RNA (siRNA) delivery system with a new pH-sensitive cationic lipid].
Sato Y; Hatakeyama H; Hyodo M; Akita H; Harashima H
Yakugaku Zasshi; 2012; 132(12):1355-63. PubMed ID: 23208041
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
